Home > Insider Trading > Filing (0001127602-12-016411)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
850693	Allergan Inc	AGN	Pharmaceutical Preparations (2834)	951622442

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1532133	J. David Endicott	2525 Dupont Drive Irvine CA 92612	Cvp And President, Agn Med	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2012-05-07	15,000	$40.16	35,352	No	4	M	Direct
Common Stock	Acquisiton	2012-05-07	12,500	$59.13	47,852	No	4	M	Direct
Common Stock	Disposition	2012-05-07	27,500	$93.81	20,352	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2012-05-07	15,000	$0.00	15,000	$40.16
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2012-05-07	12,500	$0.00	12,500	$59.13

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
15,000		2019-02-20	No	4	M	Direct
25,000		2020-02-22	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	643	Indirect	By 401(k) Trust
Common Stock	3,108	Indirect	by ESOP Trust

Footnotes

The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $93.62 to $94.10, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in this footnote.
Shares allocated to reporting person's SIP account as of reporting date.
Shares allocated to the reporting person's ESOP account as of reporting date.
The option became exercisable in four equal annual installments beginning February 20, 2010. The remaining outstanding options under this award are reported in this filing.
The option became exercisable in four equal annual installments beginning February 22, 2011. The remaining outstanding options under this award are reported in this filing.